SIGNIFICANT DIFFERENT SERUM LEVELS OF INTERLEUKIN-6 AND ADIPOKINES IN PATIENTS WITH METABOLIC SYNDROME

Ghanshyam Gahlot, Dr. Yogita Soni, Dr. Gajanand Joshi, Dr. R. K. Vyas, Dr. R. P. Agarwal

Abstract


Background & objectives: Several components of metabolic syndrome (MetS) facilitate its diagnosis, including abdominal obesity,
hyperlipidemia, high blood pressure, and insulin resistance. The production of interleukin-6 (IL-6) and adipokines seem to be associated with MetS
components. Elevated pro in flammatory cytokines show an emerging role in the patients with Metabolic syndrome. The production of interleukin-
6 seems to be strong association in patients with Met-S. These components may form a target for novel treatment approaches. The main objectives
of this study was to evaluate & estimate the serum levels IL-6 and adipokines with MetS and its components
Methods: We studied 45 subjects, with Metabolic syndrome, diagnosed by International Diabetes Federation (IDF) criteria and 45 healthy control
subjects, age below 40 years, Male subjects. We compared the circulating levels of the serum IL-6 and adipokines levels were estimated using the
ELISA in Metabolic Syndrome with onset of Type 2 Diabetes with clinical settings.
Results: Serum levels of IL-6 and adipokines were found to be significant difference between serum levels of IL-6 and adipokines in Metabolic
Syndrome with type 2 diabetic cases than in control subjects (IL-6; 27.53 ± 2.61 vs 6.07 ± 1.76 pg/ml & P < 0.001). Further, serum levels of
adiponect in were found significant decreased and serum level of leptin were found significantly increased in cases with Metabolic Syndrome and
type 2 diabetes than in control group (P < 0.001)
Interpretation & conclusions: Patients with MetS had significantly greater serum IL-6 than the controls, supporting the evidence that
inflammation plays an important role in the immunopathogenesis of the disease. Additionally, IL-6 and adipokines serum levels may predict MetS.


Keywords


IL-6, Adipokines, Metabolic Syndrome components, Diabetes Mellitus.

Full Text:

PDF

References


Cheung BM, Wat NM, Man YB, Tam S, Cheng CH, Leung GM, et al. Relationship Between the Metabolic Syndrome and the Development of Hypertension in the Hong Kong Cardiovascular Risk Factor Prevalence Study-2 (CRISPS2). The American Journal of Hypertension. 2008; 21: 17-22.

International Diabetes Federation Press Conference: The IDF consensus worldwide definition of the metabolic syndrome [article online], 2005. Available from http://www.idf.org/webdata/docs/IDF_Met asyndrome_definition.pdf. Accessed 14 April 2005.

Nakayama Y, Komuro R, Yamamoto A, Miyata Y, Tanaka M, Matsuda M, et al. Rho A induces expression of inflammatory cytokine in adipocytes. Biochemical and Biophysical Research Communications. 2009; 379: 288-92.

Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. European Cytokine Network. 2006; 17: 4-12.

Arner P. Insulin resistance in type 2 diabetes-role of the adipokines. Current Molecular Medicine. 2005; 5(3):333-9.

Langenberg C, Bergstrom J, Scheidt-Nave C, Pfeilschifter J, Barrett-Connor E. Cardiovascular Death and the Metabolic Syndrome Role of adiposity- signaling hormones and inflammatory markers. Diabetes Care. 2006;29(6):1363-9.

Devaraj S, Rosenson RS, Jialal I. Metabolic syndrome: an appraisal of the pro-inflammatory and procoagulant status. Endocrinology and Metabolism Clinics of North America. 2004;33(2):431-53.

Bastard J-P, Maachi M, van Nhieu JT, Jardel C, Bruckert E, Grimaldi A, et al. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both invivo and invitro. The Journal of Clinical Endocrinology and Metabolism. 2002;87(5):2084-9.

Anfossi G, Russo I, Doronzo G, Pomero A, Trovati M. Adipocytokines in atherothrombosis: focus on platelets and vascular smooth muscle cells. Mediators of Inflammation. 2010;2010.

Fisman EZ, Tenenbaum A. The ubiquitous interleukin-6: a time for reappraisal. Cardiovascular Diabetology. 2010;9(1):1.

Bautista L, Vera L, Arenas I, Gamarra G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF- α) and essential hypertension. Journal of Human Hypertension. 2005;19(2):149-54.

Moon Y-S, Kim D-H, Song D-K. Serum tumor necrosis factor-α levels and components of the metabolic syndrome in obese adolescents. Metabolism. 2004;53(7):863-7.

Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. The Journal of Clinical Investigation. 1995;95(5):2409.

Saghizadeh M, Ong JM, Garvey WT, Henry RR, Kern PA. The expression of TNF alpha by human muscle. Relationship to insulin resistance. The Journal of Clinical Investigation. 1996;97(4):1111.

Tzanavari T, Giannogonas P, Karalis KP. TNF- alpha and obesity. Current Directions in Autoimmunity. 2010;11:145-56.

Swaroop JJ, Rajarajeswari D, Naidu J. Association of TNF-α with insulin resistance in type 2 diabetes mellitus. The Indian Journal of Medical Research. 2012;135(1):127.

Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circulation Research. 2005; 96(9):939-49.

Hung J, McQuillan BM, Chapman CM, Thompson PL, Beilby JP. Elevated interleukin-18 levels are associated with the metabolic syndrome independent of obesity and insulin resistance. Arteriosclerosis, Thrombosis, and Vascular Biology. 2005; 25(6):1268-73.

Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. The Journal of the American Medical Association. 2001; 286(3):327-34.

Lukic L, Lalic NM, Rajkovic N, Jotic A, Lalic K, Milicic T, et al. Hypertension in obese type 2 diabetes patients is associated with increases in insulin resistance and IL-6 cytokine levels: potential targets for an efficient preventive intervention. The International Journal of Environmental Research and Public Health. 2014; 11(4):3586-98.

Sarbijani HM, Khoshnia M, Marjani A. The association between Metabolic Syndrome and serum levels of lipid peroxidation and interleukin-6 in Gorgan. Diabetes and Metabolic Syndrome. 2015.

Kitsios K, Papadopoulou M, Kosta K, Kadoglou N, Chatzidimitriou D, Chatzopoulou F, et al. Interleukin-6, Tumor Necrosis Factor alpha and Metabolic Disorders in Youth. The Journal of Clinical Endocrinology and Metabolism. 2012;2(3):120-7.

Salmenniemi U, Ruotsalainen E, Pihlajamäki J, Vauhkonen I, Kainulainen S, Punnonen K, et al. Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome. Circulation. 2004;110(25):3842-8.

Choi K, Lee J, Lee K, Seo J, Oh J, Kim S, et al. Comparison of serum concentrations of C-reactive protein, TNF-α, and interleukin 6 between elderly Korean women with normal and impaired glucose tolerance. Diabetes Research and Clinical Practice. 2004;64(2):99-106.

Aldaham S, Foote JA, Chow H-HS, Hakim IA. Smoking Status Effect on Inflammatory Markers in a Randomized Trial of Current and Former Heavy Smokers. International Journal of Inflammation. 2015; 2015.

Mandler RN, Biddison W, Mandler R, Serrate S. beta-Endorphin augments the cytolytic activity and interferon production of natural killer cells. The Journal of Immunology. 1986;136(3):934-9.

Gein S, Gorshkova K, Tendryakova S. Regulation of interleukin-1β and interleukin-8 production by agonists of μ and δ opiate receptors in vitro.Neuroscience and Behavioral Physiology. 2009; 39(6):591-5.

Bastami S, Norling C, Trinks C, Holmlund B, Walz TM, Ahlner J, et al. Inhibitory effect of opiates on LPS mediated release of TNF and IL-8. Acta Oncologica. 2013;52(5):1022-33.

Bonnet M-P, Beloeil H, Benhamou D, Mazoit J-X, Asehnoune K. The μ opioid receptor mediates morphine-induced tumor necrosis factor and interleukin-6 inhibition in toll-like receptor 2- stimulated monocytes. Anesthesia and analgesia. 2008;106(4):1142-9.

Bhargava HN, Thomas PT, Thorat S, House RV. Effects of morphine tolerance and abstinence on cellular immune function. Brain Research. 1994;642(1):1-10.

Andjelkov N, Elvenes J, Martin J, Johansen O. Opiate regulation of IL-1beta and TNF-alpha in cultured human articular chondrocytes. Biochemical and Biophysical Research Communications. 2005;333(4):1295-9.

Meijerink H, Indrati A, Utami F, Soedarmo S, Alisjahbana B, Netea MG, et al. Heroin Use Is Associated with Suppressed Pro-Inflammatory Cytokine Response after LPS Exposure in HIV- Infected Individuals. PLOS ONE. 2015;10(4):e0122822.


Refbacks

  • There are currently no refbacks.